

OVERVIEW – Monday, 21 September 2009

Room	Plenary	Harvard	Stanford	Princeton	Foyer
Time					
09.15 – 10.15	Opening Ceremony				Registration 08.00 – 18.00
10.15 – 11.00	PL-01 Gene-environment interaction				
11.00 – 11.30	Coffee Break				
11.30 – 13.00	S-01 What can we learn from genetic research for the treatment of schizophrenia?	S-02 From stigma research to mental health policy	S-03 Prevention of psychosis – current state and evolving strategies	S-04 Treatment of first episode psychosis: Functional outcome and relapse rate	
13.00 – 14.30	Lunch Break				13.30 – 14.30 h P-01, P-02, P-03, P-04
14.30 – 16.00	S-05 Approaches towards a re-classification of schizophrenia	S-06 Working together: Vocational recovery in early psychosis	S-07 New genetic results from the German Competence Network on Schizophrenia and beyond	S-08 The immune system's impact in pathophysiology and therapy of schizophrenia	
16.00 – 16.30	Coffee Break				
16.30 – 18.00	S-09 Neuroimaging in schizophrenia research	S-10 Addressing stigma – a quality feature for best psychiatric care	W-01 Classification of psychotic disorders: Considerations for DSM-V and ICD-11	O-01 Diagnosis and symptomatology	
18.00 – 19.00	Welcome Reception in the Foyer				

Abbreviations

S – Symposium

PL – Plenary

O – Oral Presentation

P – Guided Poster Tour

W – Workshop

OVERVIEW – Tuesday, 22 September 2009

Room	Plenary	Harvard	Stanford	Princeton	Foyer
08.30 – 10.00	S-11 Early course and recognition of psychosis	S-12 Polypharmacy in schizophrenia – is there a rationale?	S-13 Schizophrenia as a disorder of default regeneration: Facts and treatment options	O-02 Neuro-psychology I	Registration 08.00 – 18.30
10.00 – 10.30	Coffee Break				
10.30 – 12.00	S-14 Current results from the European Prediction of Psychosis Study (EPOS)	S-15 European practice guidelines: Survey and implementation	S-16 Can a translational approach lead to novel diagnostic and therapeutic perspectives in schizophrenia?	O-03 Neuro-psychology II	
12.15 – 13.00	PL-02 Early recognition and early intervention				
13.00 – 14.30	Lunch Break				
14.30 – 16.00	S-17 Motivational loss and mood symptoms in first episode psychosis	S-18 New psychosocial treatment options in schizophrenia	S-19 Interventions in people at risk of psychosis: Recent approaches	O-04 Neuro-imaging	
16.00 – 16.30	Coffee Break				
16.30 – 18.00	S-20 First-episode schizophrenia: Early diagnosis, short- and long-term outcome	S-21 Recovery and assertive community treatment in first psychosis	S-22 Controversies about anti-psychotics: From bench to bed side	O-05 Treatment	
18.15 – 19.45	S-23 Establishing the validity of community screening to identify children displaying the antecedents of schizophrenia	S-24 Addressing the pathophysiology of hallucinations to tailor rTMS treatment	W-02 Assessment of outcome to antipsychotic therapy beyond symptom improvement	O-06 Early stages of schizophrenia	

OVERVIEW – Wednesday, 23 September 2009

Room	Plenary	Harvard	Stanford	Princeton	Foyer
Time					
08.30 – 10.00	S-25 Is neurocognitive dysfunction a core feature of schizophrenia?	S-26 Obstacles in the management of schizophrenia patients	S-27 Neurobiology of schizophrenia and comorbid cannabis abuse	S-28 Phenotypes and the genetics of schizophrenia	Registration 08.00 – 18.00
10.00 – 10.30	Coffee Break				
10.30 – 12.00	S-29 Are there any valid neuro-functional and neurostructural endophenotypes for schizophrenia?	W-03 Comparative effectiveness of antipsychotics in the treatment of schizophrenia: Guidelines for clinical practice	S-30 Positive Symptoms of Psychosis: Psychological models and psychotherapeutic interventions	S-31 What can animal models of schizophrenia tell us about basic cognition and risk-related phenotypes?	
12.15 – 13.00	PL-03 Psychological treatments in schizophrenia				
13.00 – 14.30	Lunch Break				13.30 – 14.30 h P-08, P-09, P-10, P-11
14.30 – 16.00	S-32 Large scale proteomic and gene expression studies on post-mortem brains in schizophrenia: What have we gained?	S-33 Cognitive remediation and social functioning in schizophrenia	S-34 Prediction of neuroleptic treatment response in schizophrenia	S-35 Neurobiological and neuro-cognitive findings in persons at risk for psychosis	
16.00 – 16.30	Coffee Break				
16.30 – 17.00	Closing Ceremony				
17.00 – 18.30		O-07 Comorbidity	S-37 Learning potential and related concepts in schizophrenia: From neuro-biology to clinical practice	S-38 Cycloid psychoses: From clinical concepts to biological foundations	